Reclassification of orlistat [Xenical; Roche] as a pharmacist-only medicine has been recommended in New Zealand (NZ)

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1474, 2005-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Zealand Pharmacists and Pharmacist‐Only Medicines

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 34, Iss. 4, 2004-12 ,pp. : 282-284

John Wiley & Sons Inc

Access to resources Recommend Favorite

The New Zealand (NZ) Centre for Adverse Reactions Monitoring has received 14 reports of facial skin damage

Reactions Weekly, Vol. 1, Iss. 1081, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

A record price of $US20 000 has been revealed by manufacturing partners Roche and Trimeris for a one-year supply of their new drug enfuvirtide [`Fuzeon']

Inpharma, Vol. 1, Iss. 1380, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A 23% market share of new prescriptions for hepatitis C in the US has been captured by Roche's antiviral agent PEG-interferon (IFN)- -2a

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 402, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

A record price of $US20 000 has been revealed by manufacturing partners Roche and Trimeris for a one-year supply of their new drug enfuvirtide [`Fuzeon']

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 405, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite